Compare Sibanye Stillwater Ltd (SBSW) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sibanye Stillwater Ltd vs TG Therapeutics Inc — how do they compare? Sibanye Stillwater Ltd trades at $10 (market cap $6.88B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and Sibanye Stillwater Ltd pays a 8.17% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sibanye Stillwater Ltd for 51 Days and TG Therapeutics Inc for 16 Days on average.
| SBSW | TGTX | |
|---|---|---|
Market Cap | $6.88B | $8.16B |
Volume | 4,474,536 | 1,735,121 |
Sector | Basic Materials | Health |
52-Week High | $21.12 | $59.06 |
52-Week Low | $8.00 | $26.94 |
Typical Hold Time | 51 Days | 16 Days |
Enterprise Value | $7.78B | $8.37B |
Dividend Yield | 8.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sibanye Stillwater (SBSW) trades at $9.91, up 2.38% today, showing mixed technical signals with a bearish overall trend but neutral oscillators. Fundamentally, the company reported strong revenue growth to $129.68 billion in 2025 with improving margins, though net income remains negative. Recent Q2 2026 earnings beat expectations with EPS of $1.34 versus $1.26 expected, indicating operational momentum. Analyst sentiment is cautiously optimistic with a Moderate Buy consensus and $14.25 price target representing 44% upside potential.
The stock presents a turnaround opportunity with attractive valuation metrics (P/E 8.12, P/S 0.7) and strong cash flow generation, but faces risks from volatile commodity prices and persistent negative earnings. Institutional ownership is growing with recent 81.4% position increase by MAC Alpha Capital. The key catalyst remains sustained profitability improvement and execution of the 2027-2028 growth roadmap.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
